Date: 2012-03-05
Type of information: Grant
Company: Exonhit (France)
Investors:
Amount: €418,000
Funding type: grant
Planned used: The grant will be used to identify molecular signatures and to develop associated tests bases on Exonhit\'s proprietary Genome Wide SpliceArray ® (GWSA).
Others: Exonhit has announced that the company is beneficiary of a €418,000 grant from the European Union through its participation in the RESPONSIFY consortium financed under the 7th Framework Programme for Research and Technological Development (FP7).
RESPONSIFY is a European consortium of 12 partners focusing on personalized medicine in oncology. Its objective is to identify predictive biomarkers of response to two common chemotherapeutic treatments of breast cancer, anti-HER2 (Herceptin) and anti-angiogenic (Avastin) therapies. The goal is to develop CE marked IVD tests that will be approved for current clinical practice. The consortium is granted a total of approximately €6 million, of which € 4.8 million will be received at inception of the programme. Exonhit brings to the project the power of its proprietary Genome Wide SpliceArray® (GWSA)
platform, which will be used to analyze patient transcriptomic profiles, as well as its demonstrated ability to develop and register diagnostic tests. The Company will be in charge of filing for IP protection with respect to relevant molecular signatures and associated tests, as well as ensuring CE marking and commercialization of predictive tests identified on its platform.
In this programme, coordinated by the Charité University Hospital from Berlin, Exonhit will work together with prestigious academic partners (German Breast Group Forschungs clinical network,Basel University, Institut Jules Bordet from Brussels, Karolinska Institutet from Stockholm, University College of London and Institut Gustave Roussy in Paris), and several European industrial partners.
Therapeutic area: Cancer - Oncology
